Alastair Lamb, MD, FRCS

University of Oxford

My clinical focus is to deliver excellent and timely prostate cancer care to men referred to our team from the Oxford regional area, focussing on state-of-the-art diagnostics with multiparametric MRI and targeted transperineal biopsies, followed by robotic-radical prostatectomy (RARP) or indeed active surveillance where appropriate. Complimentary treatment modalities such as radiation or brachytherapy are provided by other members of our dedicated prostate cancer team. I have a particular interest in developments relating to minimal access surgery and simulated training, and in investigating the role of robotic surgery in locally advanced or metastatic disease.

My research goal is to provide a robust molecular platform for accurate decision-making in early stage PCa. I have spent my scientific training investigating how individual genes or groups of genes have driven PCa behaviour. My PhD thesis investigated the role of HES6 as a transcriptional driver in castrate resistant prostate cancer – we found that this single gene fundamentally changed the nature of prostate cancer cells. During this time I was funded by the Cambridge Biomedical Research Centre (NIHR) and GlaxoSmithKline. Subsequently, I developed an interest in integrated genomics in prostate cancer risk stratification as well as disease modelling with patient derived xenografts. In October 2018 I commenced a five-year Cancer Research UK funded Clinician Scientist Fellowship to undertake the SPACE Study, a translational research programme centred on identification the ‘lethal clone’ in high risk localised prostate cancer incorporating integrated genomics of targeted biopsies, spatial transcriptomics of whole prostates and data-driven tracking of clonal phylogenetics including in micro-metastatic disease. I also have an interest in novel molecular imaging techniques such as PSMA PET-CT and their use in disease stratification and decision-making before, during and after radical therapies. I am co-chief investigator of the TRANSLATE Trial and a local investigator for the PROMOTE, PART & FINESSE trials.

Disclosure information not submitted.

Presentation(s):

• MP45-14: The spatial landscape of clonal somatic mutations in benign and malignant prostate epithelia

  Sunday, May 15, 2022
  1:00 PM – 2:15 PM

• Next Generation Screening for Prostate Cancer

  Sunday, May 15, 2022
  2:00 PM – 3:20 PM

• Session Introduction

  Sunday, May 15, 2022
  2:01 PM – 2:05 PM